Vertex Pharmaceuticals recently presented updated interim data at the 2025 ASN Kidney Week, revealing significant proteinuria ...

PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous formulation ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial ...

New research reveals that contrary to conventional belief, primary glomerular diseases are not necessarily benign for ...

Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with ...

Vertex Pharmaceuticals (VRTX) announced updated data for povetacicept in IgA nephropathy and primary membranous nephropathy from the ongoing ...

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented in-person at American Society of Nephrology Kidney Week 2025 November 5–9.

The Honourable Marjorie Michel, Minister of Health, Claude Guay, Parliamentary Secretary to the Minister of Energy and Natural Resources and Member of Parliament for LaSalle-Émard-Verdun, and ...

New research reveals that contrary toconventional belief, primary glomerular diseases are not necessarily benign for children ...

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at ...

Primary glomerular diseases in children and young adults can cause rapid kidney function decline, increasing lifetime risk of ...

New research reveals that contrary toconventional belief, primary glomerular diseases are not necessarily benign for children and young adults. In ...